| 0.35 0.015 (4.57%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.57 | 1-year : | 0.7 |
| Resists | First : | 0.49 | Second : | 0.6 |
| Pivot price | 0.39  |
|||
| Supports | First : | 0.31 | Second : | 0.26 |
| MAs | MA(5) : | 0.33 |
MA(20) : | 0.42 |
| MA(100) : | 0.48 |
MA(250) : | 0.62 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.7 |
D(3) : | 6.9 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 1.25 | Low : | 0.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PAVM ] has closed above bottom band by 26.1%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.36 - 0.36 | 0.36 - 0.36 |
| Low: | 0.32 - 0.32 | 0.32 - 0.33 |
| Close: | 0.35 - 0.35 | 0.35 - 0.35 |
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Fri, 10 Oct 2025
PAVmed (PAVM) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Tue, 07 Oct 2025
Commercial phase launch: Veris platform deployed at OSUCCC–James by PAVmed to expand care - Stock Titan
Tue, 07 Oct 2025
PAVmed subsidiary Veris Health launches cancer care platform at OSU center - Investing.com
Mon, 06 Oct 2025
Ascendiant Capital Maintains PAVmed (PAVM) Buy Recommendation - Nasdaq
Thu, 11 Sep 2025
PAVmed’s Lucid Diagnostics Completes Public Stock Offering - TipRanks
Tue, 26 Aug 2025
PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | -12 (M) |
| Shares Float | -15 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 2.193e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 14,760 (K) |
| EPS | -99.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.655e+007 |
| Profit Margin | 7 % |
| Operating Margin | 144.8 % |
| Return on Assets (ttm) | -78 % |
| Return on Equity (ttm) | 583.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 21.76 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.9916e+006 |
| Qtrly Earnings Growth | -487000 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -916667 |
| Dividend | 438980 |
| Forward Dividend | 10.64 |
| Dividend Yield | 125423000% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|